Glycine reuptake inhibitor RG1678: A pharmacologic characterization of an investigational agent for the treatment of schizophrenia

Dysfunctional N-methyl-d-aspartate (NMDA) receptor neurotransmission has been implicated in the pathophysiology of schizophrenia. It is thought that this abnormal functioning can be corrected by increasing availability of the NMDA co-agonist glycine through inhibition of glycine transporter type 1 (GlyT1). Herein is described the pharmacologic profile of RG1678, a potent and noncompetitive glycine reuptake inhibitor. In vitro, RG1678 noncompetitively inhibited glycine uptake at human GlyT1 with a concentration exhibiting half-maximal inhibition (IC(50)) of 25 nM and competitively blocked [(3)H]ORG24598 binding sites at human GlyT1b in membranes from Chinese hamster ovary cells. In hippocampal CA1 pyramidal cells, RG1678 enhanced NMDA-dependent long-term potentiation at 100 nM but not at 300 nM. In vivo, RG1678 dose-dependently increased cerebrospinal fluid and striatal levels of glycine measured by microdialysis in rats. Additionally RG1678 attenuated hyperlocomotion induced by the psychostimulant d-amphetamine or the NMDA receptor glycine site antagonist L-687,414 in mice. RG1678 also prevented the hyper-response to d-amphetamine challenge in rats treated chronically with phencyclidine, an NMDA receptor open-channel blocker. In the latter experiment, a decrease in ex vivo striatal [(3)H]raclopride binding was also measured. These data demonstrate that RG1678 is a potent, noncompetitive glycine reuptake inhibitor that can modulate both glutamatergic and dopaminergic neurotransmission in animal experiments that model aspects of schizophrenia. This article is part of a Special Issue entitled 'Post-Traumatic Stress Disorder'.

[1]  P. Seeman,et al.  Antipsychotic drug doses and neuroleptic/dopamine receptors , 1976, Nature.

[2]  A. Carlsson,et al.  Neurotransmitter interactions in schizophrenia—therapeutic implications , 1999, Biological Psychiatry.

[3]  J. Stone Imaging the glutamate system in humans: relevance to drug discovery for schizophrenia. , 2009, Current pharmaceutical design.

[4]  Karla K Kopec,et al.  Glycine transporter (GlyT1) inhibitors with reduced residence time increase prepulse inhibition without inducing hyperlocomotion in DBA/2 mice. , 2010, Biochemical pharmacology.

[5]  S. Kingsmore,et al.  Cloning of the human glycine transporter type 1: molecular and pharmacological characterization of novel isoform variants and chromosomal localization of the gene in the human and mouse genomes. , 1994, Molecular pharmacology.

[6]  R. Malenka,et al.  Synaptic plasticity and addiction , 2007, Nature Reviews Neuroscience.

[7]  C. Parsons,et al.  Glycine and N-methyl-D-aspartate receptors: physiological significance and possible therapeutic applications. , 1998, Pharmacological reviews.

[8]  F. Jursky,et al.  Developmental Expression of the Glycine Transporters GLYT1 and GLYT2 in Mouse Brain , 1996, Journal of neurochemistry.

[9]  S. Leucht,et al.  Second-generation antipsychotics for schizophrenia: can we resolve the conflict? , 2009, Psychological Medicine.

[10]  D. Javitt Glutamatergic theories of schizophrenia. , 2010, The Israel journal of psychiatry and related sciences.

[11]  Charles R. Yang,et al.  Glycine tranporter-1 blockade potentiates NMDA-mediated responses in rat prefrontal cortical neurons in vitro and in vivo. , 2003, Journal of neurophysiology.

[12]  B. Cubelos,et al.  Localization of the GLYT1 glycine transporter at glutamatergic synapses in the rat brain. , 2005, Cerebral cortex.

[13]  J. Feldon,et al.  Interactions between the glycine transporter 1(GlyT1) inhibitor SSR504734 and psychoactive drugs in mouse motor behaviour , 2009, European Neuropsychopharmacology.

[14]  G. Griebel,et al.  The Glycine Transporter-1 Inhibitor SSR103800 Displays a Selective and Specific Antipsychotic-like Profile in Normal and Transgenic Mice , 2010, Neuropsychopharmacology.

[15]  M. Shahid,et al.  Molecular cloning and functional expression of the human glycine transporter GlyT2 and chromosomal localisation of the gene in the human genome. , 1998, FEBS letters.

[16]  W. Ju,et al.  Glycine binding primes NMDA receptor internalization , 2003, Nature.

[17]  P. Ascher,et al.  Glycine potentiates the NMDA response in cultured mouse brain neurons , 1987, Nature.

[18]  M. Laruelle Imaging dopamine transmission in schizophrenia. A review and meta-analysis. , 1998, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[19]  E. Pinard,et al.  Pharmacological evaluation of a novel assay for detecting glycine transporter 1 inhibitors and their antipsychotic potential , 2010, Pharmacology Biochemistry and Behavior.

[20]  C. Sur,et al.  The therapeutic potential of glycine transporter-1 inhibitors , 2004, Expert opinion on investigational drugs.

[21]  M. Laruelle,et al.  Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia , 2000, Biological Psychiatry.

[22]  P. Mátyus,et al.  Glycine transporter type-1 and its inhibitors. , 2006, Current medicinal chemistry.

[23]  Karel Svoboda,et al.  Structural Plasticity Underlies Experience-Dependent Functional Plasticity of Cortical Circuits , 2010, The Journal of Neuroscience.

[24]  N. Andreasen,et al.  Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. , 2005, The American journal of psychiatry.

[25]  N. Nelson,et al.  Cloning and expression of a glycine transporter from mouse brain , 1992, FEBS letters.

[26]  D. Javitt,et al.  Thinking glutamatergically: changing concepts of schizophrenia based upon changing neurochemical models. , 2010, Clinical schizophrenia & related psychoses.

[27]  Joseph E LeDoux,et al.  Synaptic plasticity in fear conditioning circuits: induction of LTP in the lateral nucleus of the amygdala by stimulation of the medial geniculate body , 1990, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[28]  T. Sharp,et al.  Measurement of GABA in rat brain microdialysates using o-phthaldialdehyde-sulphite derivatization and high-performance liquid chromatography with electrochemical detection. , 1994, Journal of chromatography.

[29]  N. B. Saul’skaya,et al.  Tetrodotoxin-Dependent Glycine Release in the Rat Nucleus Accumbens During Correction of Feeding Behavior , 2005, Neuroscience and Behavioral Physiology.

[30]  D. Javitt,et al.  Double-Blind, Placebo-Controlled, Crossover Trial of Glycine Adjuvant Therapy for Treatment-Resistant Schizophrenia , 1996, British Journal of Psychiatry.

[31]  J. Lindon,et al.  600 MHz 1H-NMR spectroscopy of human cerebrospinal fluid: effects of sample manipulation and assignment of resonances. , 1993, Journal of pharmaceutical and biomedical analysis.

[32]  S. Oja,et al.  Glycine release from hippocampal slices in developing and ageing mice: modulation by glutamatergic receptors , 1994, Mechanisms of Ageing and Development.

[33]  B. Angrist,et al.  The phenomenology of experimentally induced amphetamine psychosis--preliminary observations. , 1970, Biological psychiatry.

[34]  M. Martina,et al.  Glycine transporter type 1 blockade changes NMDA receptor‐mediated responses and LTP in hippocampal CA1 pyramidal cells by altering extracellular glycine levels , 2004, The Journal of physiology.

[35]  Kirk W. Johnson,et al.  Neurochemical and behavioral profiling of the selective GlyT1 inhibitors ALX5407 and LY2365109 indicate a preferential action in caudal vs. cortical brain areas , 2008, Neuropharmacology.

[36]  J. Morrow,et al.  Molecular cloning and functional expression of the human glycine transporter GlyT2 and chromosomal localisation of the gene in the human genome 1 , 1998 .

[37]  Paul J. Harrison,et al.  Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence , 2005, Molecular Psychiatry.

[38]  R. Buchanan,et al.  A five-year followup study of deficit and nondeficit schizophrenia , 2001, Schizophrenia Research.

[39]  J. Lisman,et al.  Requirements for LTP induction by pairing in hippocampal CA1 pyramidal cells. , 1999, Journal of neurophysiology.

[40]  Peter B. Jones,et al.  Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). , 2006, Archives of general psychiatry.

[41]  R. Dingledine,et al.  Requirement for glycine in activation of NMDA-receptors expressed in Xenopus oocytes. , 1988, Science.

[42]  A. Carlsson,et al.  Network interactions in schizophrenia — therapeutic implications 1 , 2000 .

[43]  Nicholas Lange,et al.  D-serine added to antipsychotics for the treatment of schizophrenia , 1998, Biological Psychiatry.

[44]  Nicholas Lange,et al.  Glycine transporter I inhibitor, N-Methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia , 2004, Biological Psychiatry.

[45]  B. Yamamoto,et al.  An improved and rapid HPLC-EC method for the isocratic separation of amino acid neurotransmitters from brain tissue and microdialysis perfusates. , 1988, Life sciences.

[46]  David A Lewis,et al.  Catching Up on Schizophrenia Natural History and Neurobiology , 2000, Neuron.

[47]  J. Krystal,et al.  Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. , 1994, Archives of general psychiatry.

[48]  M. Millan N-Methyl-d-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives , 2005, Psychopharmacology.

[49]  Shikha Snigdha,et al.  Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism. , 2010, Pharmacology & therapeutics.

[50]  Robert K. Heaton,et al.  Subjective and objective quality of life in schizophrenia , 2008, Schizophrenia Research.

[51]  Alexander Alanine,et al.  Selective GlyT1 inhibitors: discovery of [4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia. , 2010, Journal of medicinal chemistry.

[52]  J. Richards,et al.  Cellular expression of glycine transporter 2 messenger RNA exclusively in rat hindbrain and spinal cord , 1995, Neuroscience.

[53]  D. Javitt,et al.  Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia. , 1987, The Hillside journal of clinical psychiatry.

[54]  R. McGuire,et al.  The first potent and selective inhibitors of the glycine transporter type 2. , 2001, Journal of medicinal chemistry.

[55]  S. Oja,et al.  Mechanisms of Glycine Release in Mouse Brain Stem Slices , 2009, Neurochemical Research.

[56]  A. Brown,et al.  Pharmacological assessment of the role of the glycine transporter GlyT-1 in mediating high-affinity glycine uptake by rat cerebral cortex and cerebellum synaptosomes , 2001, Neuropharmacology.

[57]  J. Krystal,et al.  Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[58]  Chih-Chiang Chiu,et al.  Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. , 2005, Archives of general psychiatry.

[59]  Daniel C Javitt,et al.  Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions. , 2007, International review of neurobiology.

[60]  P. Leeson,et al.  The anticonvulsant and behavioural profile of L‐687,414, a partial agonist acting at the glycine modulatory site on the N‐methyl‐D‐aspartate (NMDA) receptor complex , 1994, British journal of pharmacology.

[61]  P. Mátyus,et al.  Alterations in Brain Extracellular Dopamine and Glycine Levels Following Combined Administration of the Glycine Transporter Type-1 Inhibitor Org-24461 and Risperidone , 2010, Neurochemical Research.

[62]  D. Sanger The search for novel antipsychotics: pharmacological and molecular targets , 2004, Expert opinion on therapeutic targets.